5,6-Disubstituted Pyridine Carboxamides for Selective CB2 Agonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective compounds that selectively target Cannabinoid Receptor 2 (CB2) for treating various diseases such as pain, neuropathic pain, asthma, osteoporosis, inflammation, psychiatric disorders, and immunological disorders without significant activity on Cannabinoid Receptor 1 (CB1).
Innovation Solution
Development of a compound of formula (I) that acts as a preferential inverse agonist of CB2, with specific structural features allowing it to bind and modulate the CB2 receptor with minimal activity on CB1, thereby providing therapeutic benefits for multiple conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a compound is designed to have high CB2 receptor activity for therapeutic effect, then therapeutic efficacy is improved, but CB1 receptor activity may also increase causing unwanted side effects
Solution Approach 1:
The patent applies local quality by introducing specific substituents at defined positions (R1 at position 5 or 6, and R2 at position 6 or 5) on the pyridine ring structure. These localized structural modifications create steric hindrance or electronic effects that selectively enhance CB2 binding while reducing CB1 affinity, thereby achieving therapeutic efficacy with minimized side effects
Solution Approach 2:
The patent employs asymmetry by creating non-symmetric substitution patterns on the pyridine ring (5-substitution and 6-substitution with different R groups). This asymmetric molecular architecture allows differential interaction with the asymmetric binding pockets of CB1 and CB2 receptors, enabling selective binding to CB2 while avoiding CB1 activation
2Adaptability or versatility
If existing cannabinoid therapies are used to treat multiple diseases, then broad therapeutic coverage is achieved, but lack of selectivity causes significant CB1 activity and unwanted side effects
Solution Approach 1:
The patent achieves universality by designing a pyridine-2-carboxamide core structure (formula I) that can selectively target CB2 receptors involved in multiple disease pathways including pain, inflammation, asthma, osteoporosis, and psychiatric disorders. This single selective CB2 agonist structure provides multi-disease therapeutic coverage without the need for different compounds for each condition
Solution Approach 2:
The patent applies parameter changes by systematically varying the substituents R1 and R2 at specific positions on the pyridine ring to optimize CB2 selectivity. By changing the chemical parameters (type, position, and configuration of substituents), the compound achieves high CB2 affinity while maintaining low CB1 activity, enabling broad therapeutic applications with reduced side effects
Data Source
AI summary
The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) are agonists of the Cannabinoid Receptor 2 and are therefore useful in the treatment of various diseases such as pain, atherosclerosis, inflammation etc.